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Open access unIntroduction: The treatment of choice for early glottic cancer is still being debated; ultimately it relies on
the functional outcome. This paper reports on a novel sparing 4D conformal technique for single vocal
cord irradiation (SVCI).
Material and methods: The records of 164 T1a patients with SCC of the vocal cord, irradiated in the Eras-
mus MC between 2000 and 2008, were analyzed for local control and overall survival. The quality of life
was determined by EORTC H&N35 questionnaires. Also the VHI (voice handicap index), and the TSH (thy-
roid stimulating hormone) blood levels, were established. On-line image guided SVCI, using cone beam
CT or stereotactic radiation therapy (SRT) techniques, were developed.
Results: A LC rate at ﬁve-years of 93% and a VHI of 12.7 (0–63) was determined. It appeared feasible to
irradiate one vocal cord within 1–2 mm accuracy. This way sparing of the contralateral (CL) vocal cord
and CL normal tissues, could be achieved.
Conclusions: Given the accuracy (1–2 mm) and small volume disease (CTV limited to one vocal cord), for
the use of stereotactic RT techniques SVCI with large fraction sizes is currently being investigated in
clinic. It is argued that hypofractionated SVCI can be a competitive alternative to laser surgery.
 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.
Radiotherapy and Oncology 101 (2011) 415–419Of all head and neck cancers (HNCs), approximately 30 percent
originates from the larynx. In Europe, annually 52.000 patients are
diagnosed with cancer of the larynx. Local control (LC) varies,
depending on the subsite and/or extent of the disease (T-and
N-stage). This paper analyzes patients with early glottic cancer
(EGC), that is, as deﬁned by the UICC/AJCC classiﬁcation system,
disease conﬁned to one (T1a) true vocal cord [1]. Radiation therapy
(RT) and carbon dioxide endoscopic laser surgery (LS) have both
proven to be effective treatment modalities for T1a glottic cancers.
A high cure rate is often cited using either one modality. A sum-
mary of the literature by Sjögren et al. [1,2] reported for T1 lesions
treated with RT alone a LC rate at ﬁve-years of 84% (range 78–89%)
and an average larynx preservation rate of 93%. Same author pub-
lished in 2008 on 143 T1a lesions treated by RT (70) and LS (73); a
local recurrence of 21% vs. 10% for RT and LS, respectively, was ob-
served [2]. However, 16% of the LS group needed additional treat-
ment consisting of LS (4%) and/or RT (11%). No signiﬁcant
difference in VHI was found for both treatment modalities [3].
Mendenhall and colleagues, reported in their review paper on T1
lesions treated by primary RT, local control rates of 85–94%.l Center – Daniel den Hoed
ene Hilledijk 375, 3075 EA
vendag).
der the Elsevier OA license.Recently, Mendenhall [4] updated their own results on T1, T2 glot-
tic cancer. A ﬁve-year LC rate of 94% was reported for T1a lesions.
Also, of the 585 patients analyzed, ten (1.7%) experienced severe or
fatal complications [4]. In a summary paper by Grant et al. [5], local
control rates for transoral laser microsurgery (TLM) varied
between 71% and 97% [6–20]. Cohen et al., in a meta-analysis of
non-randomized studies comparing the VHI of patients receiving
RT or LS, found the voice to be similar in both modalities
(p = 0.1) [21]. Similarly, in the most detailed retrospective study
published by Loughran et al. when using the full armamentarium
of validated scoring systems for studying vocal performance no dif-
ference was observed [22]. With regard to the quality of voice in
EGC; LS is in principle performed as a highly focussed treatment
for a clinical target volume (CTV) located on one vocal cord, while
in conventional RT, the radiation ﬁelds do not conform to the
tumor volume per se but in fact both vocal cords are irradiated.
Moreover, in a number of cases LS is still to be followed by EBRT
of the larynx.
A comparative dosimetric analysis of vocal cord irradiation
using different techniques, that is conventional (box technique)
vs. IMRT of the larynx vs. single vocal cord irradiation, has recently
been published by our group. This paper focuses on the comparison
of the dose distribution in many of the normal tissues at risk, using
either one of the aforementioned techniques. The reduction of
potential side effects, such as pain, poor quality of voice, speech,
416 Single vocal cord irradiationxerostomia, dysphagia, incidence of stroke or transient ischemic
attack following radiation of the neck, and hypothyroidism, will
be discussed. Given the fact that one is dealing with small volume
disease (CTV [part of] one vocal cord), when using SRT techniques,
the role of (hypo) fractionation can be analyzed. It is argued that
single vocal cord irradiation by hypofractionation, considering
the low probability of normal tissue side-effects, can be a future
way to treat early (T1a) glottic cancers. Good local control rates,
improvement of VHI, short overall treatment times and potential
room for retreatment with preservation of the larynx, can be
anticipated.
Materials and methods
The purpose of this paper is to report on treatment optimization
when radiating T1a vocal cord lesions. As a base line observation,
ﬁrst the results from our own institution on LC, OS, quality of life
(QoL) and voice handicap index (VHI) of EGC treated with conven-
tional radiation therapy were analyzed. For a clinical review on LS,
the reader is referred to the many papers on this issue reported in
the literature. These data have been brieﬂy summarized in the
introduction section of this paper.LC and survival using conventional radiotherapy of early glottic tumor
To analyze the LC rate and QoL results, all records of patients
with SCC of the glottis were reviewed (Fig. 1); newly diagnosed
carcinoma in situ (35 Tis), T1b lesions (38; both vocal cords) were
excluded from the present analysis. The remaining patients with
SCC of the true vocal cords (164 T1a) treated between 2000 and
2008 at our institute, were studied. All patients were simulated
in supine position; for immobilization purposes a custom made
head shell was manufactured. Lateral parallel-opposed wedgedT1a  n=164 







VHI  12.7 (0-63)
VHI Functional 3.4(0-20)
VHI Physical 6.5 (0-25)
VHI Emotional 2.7 (0-21)
* QoL mean scores (range) based on last assesment
‡ EORTC H&N35 scales; mean scores(range)
§ TSH normal range 0.4-4.3
Early Glottic Laryngeal Carcinoma 2000-2008




Dry mouth 19.6 (0-100)
Sticky saliva 17.1 (0-100)
Speech 12.7 (0-63)
Pain 7.5 (0-50)
Fig. 1. For patients treated in the Erasmus Medical Center–Daniel den Hoed Cancer
Center, Fig. 1 depicts the LC (local control) and OS (overall survival), the QoL
(quality of life) scales and VHI (voice handicap index). Also presented are the blood
levels TSH (thyroid stimulating hormone) reﬂecting the thyroid function post
radiotherapy.6 MV photon beams, mean ﬁeld size 636 cm2 [6  6 cm2], with
the iso-center placed at the center of the vocal cord lesion, were
used. One fraction per day, fraction size of 2–2.3 Gy, was given ﬁve
days per week, up to a total dose of 60–66 Gy. The dose was pre-
scribed according to ICRU guidelines (with dose in the target vary-
ing between 95% and 107%) [23]. The absence of a lymphatic
network and consequently the low incidence of nodal spread do
not warrant elective nodal irradiation. Patients of the current series
were analyzed for local control with or without salvage, and overall
survival. Also, QoL using the EORTC H&N35 questionnaires, the
quality of voice using the VHI (voice handicap index), and the thy-
roid function status (TSH [thyroid stimulating hormone] blood lev-
els), were determined.Intensity modulated radiotherapy for T1a early glottic cancers, single
vocal cord irradiation technique
Ten patients with T1aN0M0 glottic carcinomas were previously
treated at our institute by lateral P-O ﬁelds (box technique), and
were retrospectively used for the current investigation. The con-
ventional treatment plans were originally made using the CadPlan
treatment planning system (Varian Medical Systems, Palo Alto,
USA), and were regenerated in the XiO treatment planning system
(V 4.33 Elekta-CMS Software), using heterogeneity corrections and
a fast convolution superposition algorithm. In all planning CT scans
(resolution 1 mm3) the clinical target volume (CTV, margin 3 mm)
and the organs at risk (OARs) were delineated. The delineated
structures were the vocal cords, arytenoids, swallowing muscle
at the level of the vocal cords (inferior constrictor muscle, ICM),
ipsi- and contra-lateral strap muscles, carotid arteries, thyroid
gland, thyroid and cricoid cartilages, and the spinal cord. The cra-
nial–caudal extensions of the contours of these OARs were at the
level of the vertebra C2 and C7. IMRT and SVCI treatment planning
was performed for an Elekta Synergy linear accelerator with 40
MLC leaf pairs and a leaf width at the isocenter of 4 mm (Elekta
Beam ModulatorTM, Elekta Oncology Systems, Crawley, UK) at
6 MV. The minimum segment size allowed was 0.5 cm2. The iso-
center of the treatment was set to the center of one of the vocal
cords. The radiation schedule proposed to be used in combination
with the SVCI technique, is discussed in the next section.Results and discussion
Laser surgery or radiotherapy
Carbon dioxide endoscopic LS is an established treatment tech-
nique for early glottic cancer. According to Sjögren et al. [2] LS was
introduced in the Leiden University Medical Center, for T1a mid-
cord lesions, in 1996. The results were summarized as follows;
‘‘T1a glottic carcinoma allocated to radiotherapy have a poorer out-
come in terms of local control and laryngectomy free survival than
do T1a patients selected for laser surgery’’. Motta et al. [24] as-
sessed the vocal function of patients who had undergone CO2 laser
cordectomy. No functional compensation enabled the patients to
achieve a voice quality comparable with that of controls. Vilaseca
et al. [25] studied the voice quality after CO2 laser cordectomy.
They concluded that the voice improved in almost 60% of the
patients, returning to normal in 45%. Nunez et al. [26] analyzed
functional outcome and self-evaluation of the voice of patients
with T1 glottic carcinoma treated with endoscopic LS and RT.
When comparing the VHI scores, this was in apparent favor for
RT, in functional and emotional ratings as well as for the global
scores. VHI scores of the T1a larynx cancer group after radiother-
apy in our hospital has been listed in Table 1.
Despite the (sometimes contradictory) reports on post-treat-
ment voice quality, it is mostly agreed upon that radiotherapy
Table 1
Mean and range of the VHI-scores T1a larynx group after
radiotherapy. VHI: voice handicap index, VHI-F: VHI-functional,
VHI-E: VHI-emotional, VHI-P: VHI-physical.
VHI-total, mean (range) 12.7 (0–63)
VHI-F, mean (range) 3.4 (02–0)
VH-E, mean (range) 2.7 (0–21)
VHI-P, mean (range) 6.5 (0–25)
Table 2
Mean dose to PTV, CTV and critical structures.






PTV Mean ± SD 67 ± 1 67 ± 1 67 ± 1
CTV Mean ± SD 67 ± 1 67 ± 1 67 ± 1
CL vocal cord Mean ± SD 39 ± 8 (n.a.) 67 ± 1
IL arytenoid Mean ± SD 64 ± 3 65 ± 1 66 ± 1
CL arytenoid Mean ± SD 20 ± 8 66 ± 2 66 ± 1
ICM Mean ± SD 28 ± 4 39 ± 5 61 ± 3
IL strap
muscle
Mean ± SD 17 ± 2 18 ± 3 49 ± 8
CL strap
muscle
Mean ± SD 9 ± 4 18 ± 3 49 ± 10
Thyroid gland Mean ± SD 3 ± 1 3 ± 1 17 ± 11
Thyroid gland Max ± SD 10 ± 8 10 ± 9 15 ± 11
Thyroid
cartilage
Mean ± SD 28 ± 5 38 ± 7 66 ± 1
Cricoid Mean ± SD 22 ± 4 28 ± 4 61 ± 4
IL carotid
artery
Max ± SD 24 ± 5 31 ± 4 66 ± 3
CL carotid
artery
Max ± SD 12 ± 2 30 ± 5 66 ± 2
Spinal cord Max ± SD 22 ± 10 27 ± 6 2 ± 0
IL = ipsi-lateral, CL, contra-lateral.
P.C. Levendag et al. / Radiotherapy and Oncology 101 (2011) 415–419 417results in equal or even better voice quality post treatment as
opposed to LS [3]. Moreover, even better outcomes are to be ex-
pected with the emerging more focused RT techniques (see below).
Apart from this, the comparison of LS with conventional RT tech-
niques is not really valid due to patient selection. For example,
since patients treated for small, early lesions are exposed more
commonly to LS and, therefore, a favorable outcome for this pa-
tient group is anticipated. This bias can only be overcome by the
design of prospective randomized trials.
In addition to a localized tumor growth conﬁned to one or both
vocal cords, geometrically complex tumors could also be treated
with RT using IMRT techniques and still achieve excellent normal
tissue sparing. These include tumors involving the anterior com-
missure (AC) which are most often not amenable for LS. Moreover,
for T2 tumors extending into to the sub- or supra-glottic regions, so
far insufﬁcient data with regard to LS are available.CL Arytenoid CTV(T1a)
100
90
SVCI- IMRT Conventional PORTSingle vocal cord irradiation (SVCI) with IMRT
In the Erasmus Medical Center a study was undertaken by
Osman et al. on the feasibility of unilateral vocal cord irradiation
(SVCI) for T1a lesions. The concept was to see whether unilateral
vocal cord irradiation could reliably be re-produced on a daily basis
(i.e. in case of fractionated RT). In 2008, our ﬁrst study was pub-
lished showing that the intra-fraction movement of the vocal cords
was small and not prohibitive for executing such a delicate treat-
ment technique [27]. A second publication dealt with the adequacy
of daily on-line re-positioning [28]. A subsequent paper showed
the superiority of IMRT as opposed to lateral P-O irradiation tech-















































Fig. 2. An example of typical dose volume histograms (DVH) comparing the dose
received by the CTV (panel 1). Also depicted are the organs at risk when using
conventional parallel opposed beam (dotted lines), and IMRT for single cord
irradiation (solid lines), respectively.Risk of ischemic vascular side effects after neck irradiation
In recent years attention has increasingly been devoted to
vascular effects when radiation is the treatment of choice for a pri-
mary cancer in the head & neck region [30,31]. RT of the head and
neck is found to be a signiﬁcant risk factor for carotid artery steno-
sis. In a paper by Brown et al. [30], an incidence of 18% carotid ar-
tery stenosis in the ipsilateral irradiated neck vs. 7% in the
contralateral non-irradiated neck was reported. Lateral P-O portals
include in part the carotid arteries; consequentially, since one of
the causes of stroke is carotid artery stenosis. Stroke could be con-
sidered as a typical side effect associated with irradiation of the
head and neck. According to Dorrestein et al. [32], the overall risk
of strokes after RT was signiﬁcantly increased compared to the
general population. Rosenthal et al. [31] concluded from a litera-
ture survey that 50 Gy could be considered the approximate
threshold dose for vascular (i.e. carotid arteries) damage in the
neck after post-irradiation. Consequently, treatment options for
previously irradiated patients (with conventional RT methods)
are potentially limited due because of increased risk for carotid in-
jury. In our planning study using SVCI techniques with IMRT, no
part of the carotid arteries received doses as high as 50 Gy (see
mean and maximum dose received by the carotid arteries Table
2). Therefore, this might allow for re-irradiation of these tumors.
In conclusion, additional treatment options for recurrent tumors
or second primary tumors in the upper aerodigestive track areanother beneﬁt for using IMRT. These tumors are usually salvaged
with surgery with very generous surgical margins (e.g. by laryn-
gectomy), obviously negating the effect on the QoL of these
patients.Hypothyroidism
Hypothyroidism remains an underreported and often under-
appreciated late sequel of RT or thyroid surgery [33]. Early
418 Single vocal cord irradiationrecognition and suppletion with thyroid hormones may prevent
the development of clinical symptoms of hypothyroidism. In the
laboratory of the Erasmus MC, TSH normal values range from 0–
4.3 mUnits. In the patients under investigation, a maximum of 6%
had abnormal values of TSH (that is outside the normal range),
see also Fig. 1. This low number is probably due to the anatomical
position of the thyroid gland. Thus, a small dose is apparently to be
received by the thyroid glands with normal anatomical positioning
(see Table 2 in general). However, a simple TSH routine check in
follow-up is still worthwhile for picking up these isolated cases
(6%). A detailed analysis of hypothyroidism is beyond the scope
of the present paper.Radiotherapy for the management of early glottic tumors
A comparison of the dose received by the various structures
from the different radiotherapy techniques is shown in Figs. 2
and 3. In Fig. 2 examples of typical dose-volume-histogram
(DVH) comparisons are shown, illustrating the dose received by
the vocal cords, arytenoids, inferior constrictor muscle (ICM),
spinal cord, strap muscles, and the arytenoids when using lateral
P-O wedged photon beams (dotted lines), and IMRT for a single
vocal cord (solid lines). In the lateral P-O beam plans most of the
structures receive the full dose as opposed to IMRT plans, where
notable sparing of normal tissue is obtained (also see Table 2).
Fig. 3 shows examples of three dose distributions; column (A)(A)SVCI-IMRT (B)TVCI-IM
Fig. 3. Transverse (top), coronal (middle), sagittal (bottom) slices showing typical dose di
IMRT for both vocal cords (second column), and P-O plans (third column).for SVCI with IMRT for a T1a tumor on the right vocal cord. In
addition, in column B, an example of a T1b–IMRT plan is shown
for both vocal cords. Finally, column C, a typical dose distribu-
tion for lateral P-O beams is presented. At present accurate
treatment techniques are available to apply highly focused radi-
ation, e.g. with the use of cone beam CT and stereotactic radia-
tion. Given the small target and the large amount of sparing of
different normal tissues, apparently the CTV and PTV margin
can be small and the beneﬁt of hypofractionation becomes an is-
sue. We have, therefore, proposed to start a clinical pilot study
using ﬁve fractions of 8.5 Gy per fraction, with the dose pre-
scribed to the 80% isodose line. Finally, we have not discussed
the issue of costs per treatment modality since they differ sub-
stantially given the variations in health care providers (national
guidelines) per country.Conclusion
Treatment modalities of T1 vocal cord lesions differ substan-
tially per institution. Many of the selection factors involved were
evaluated in this study in order to arrive at the best treatment
option. The analyzed selection factors were LC, OS, QoL, preserva-
tion of voice, potential for vascular side effects, and hypothyroid-
ism. The weight given to each of the QoL factors and the
potential side effects of LS will guide the preference for either LS
or RT. The outcome in QoL and the preservation of voice have, inRT (C) Conventional PO
stributions (iso-dose ﬁll) obtained using IMRT for the right vocal cord (ﬁrst column),
P.C. Levendag et al. / Radiotherapy and Oncology 101 (2011) 415–419 419general, favorably been reported for RT; this is despite the fact the
RT involves a larger surface area than is the case with LS (i.e. two
vocal cords in stead of one). Vascular side effects and hypothyroid-
ism are not present when using LS. The risk for the occurrence of
these side effects is, however, extremely small in the case of RT
and can be further reduced by using advanced RT techniques, such
as IMRT and SVCI. For good reasons (see paragraph before), it has
been argued to start the clinical testing of the role of hypofraction-
ation in these very small target volumes. Finally, of obvious advan-
tage is the fact that RT is a non-invasive technique. However, in
terms of evidence based medicine, randomized trials for the out-
come of SVCI by IMRT techniques and LS are absent but are deﬁ-
nitely needed in order to make a more balanced comparison for
these competitive techniques.
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